These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38196545)

  • 61. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination.
    Tella SH; Kommalapati A; Mahipal A; Jin Z
    Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Immunotherapy in Hepatogastroenterology - update 2022: efficacy and immune-related adverse events].
    Krimmel L; Quante M; Bengsch B
    Dtsch Med Wochenschr; 2023 Mar; 148(6):294-300. PubMed ID: 36878227
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.
    Feng GS; Hanley KL; Liang Y; Lin X
    Hepatology; 2021 Jan; 73 Suppl 1(Suppl 1):104-114. PubMed ID: 32715491
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?
    Nordness MF; Hamel S; Godfrey CM; Shi C; Johnson DB; Goff LW; O'Dell H; Perri RE; Alexopoulos SP
    Am J Transplant; 2020 Mar; 20(3):879-883. PubMed ID: 31550417
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma.
    De Wilde N; Vonghia L; Francque S; De Somer T; Bagdadi A; Staub E; Lambrechts J; Bucalau AM; Verset G; Van Steenkiste C
    World J Hepatol; 2022 Aug; 14(8):1608-1620. PubMed ID: 36157862
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study.
    Kudo M; Aoki T; Ueshima K; Tsuchiya K; Morita M; Chishina H; Takita M; Hagiwara S; Minami Y; Ida H; Nishida N; Ogawa C; Tomonari T; Nakamura N; Kuroda H; Takebe A; Takeyama Y; Hidaka M; Eguchi S; Chan SL; Kurosaki M; Izumi N
    Liver Cancer; 2023 Sep; 12(4):321-338. PubMed ID: 37901197
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
    Griffiths CD; Zhang B; Tywonek K; Meyers BM; Serrano PE
    JAMA Netw Open; 2022 Jul; 5(7):e2222721. PubMed ID: 35849393
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial.
    Lee YC; Huang WT; Lee MY; Tsao CJ; Feng YH
    In Vivo; 2023; 37(1):454-460. PubMed ID: 36593061
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hepatocellular Carcinoma Immunotherapy.
    Sperandio RC; Pestana RC; Miyamura BV; Kaseb AO
    Annu Rev Med; 2022 Jan; 73():267-278. PubMed ID: 34606324
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Systemic treatment for unresectable hepatocellular carcinoma.
    Leowattana W; Leowattana T; Leowattana P
    World J Gastroenterol; 2023 Mar; 29(10):1551-1568. PubMed ID: 36970588
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Status Quo and Development of Immunotherapy for Hepatocellular Carcinoma].
    Wang T; Wang WT
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):692-698. PubMed ID: 37248607
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials.
    Cammarota A; Zanuso V; D'Alessio A; Pressiani T; Bozzarelli S; Personeni N; Rimassa L
    Expert Opin Investig Drugs; 2022 Apr; 31(4):425-435. PubMed ID: 35152830
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation.
    Li M; Bhoori S; Mehta N; Mazzaferro V
    J Hepatol; 2024 Jun; ():. PubMed ID: 38848767
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports.
    Al Zahrani A; Alfakeeh A
    J Med Case Rep; 2021 Mar; 15(1):132. PubMed ID: 33722275
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis.
    Rizzo A; Carloni R; Ricci AD; Cusmai A; Laforgia M; Calabrò C; Ungaro V; Oreste D; Sollitto M; Palmiotti G; Brandi G
    Expert Opin Drug Saf; 2023 Apr; 22(4):323-329. PubMed ID: 36426773
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial.
    Li D; Toh HC; Merle P; Tsuchiya K; Hernandez S; Verret W; Nicholas A; Kudo M
    Liver Cancer; 2022 Dec; 11(6):558-571. PubMed ID: 36589722
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma.
    Shen W; Chen Y; Lei P; Sheldon M; Sun Y; Yao F; Ma L
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291797
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience.
    Sinner F; Pinter M; Scheiner B; Ettrich TJ; Sturm N; Gonzalez-Carmona MA; Waidmann O; Finkelmeier F; Himmelsbach V; De Toni EN; Ben Khaled N; Mohr R; Fründt TW; Kütting F; Bömmel FV; Lieb S; Krug S; Bettinger D; Schultheiß M; Jochheim LS; Best J; Müller C; Keitel V; Venerito M
    Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497447
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma.
    Manzar GS; De BS; Abana CO; Lee SS; Javle M; Kaseb AO; Vauthey JN; Tran Cao HS; Koong AC; Smith GL; Taniguchi CM; Holliday EB; Das P; Koay EJ; Ludmir EB
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.